Legal & General Group PLC Savara Inc Transaction History

Legal & General Group PLC

$368 Billion
Q4 2024

A detailed history of Legal & General Group PLC transactions in Savara Inc stock. As of the latest transaction made, Legal & General Group PLC holds 95,577 shares of SVRA stock, worth $262,836. This represents 0.0% of its overall portfolio holdings.

Number of Shares

95,577

Previous 108,190 11.66%

Holding current value

$262,836

Previous $458,000 36.03%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	SELL	$2.94 - $4.07 $37,082 - $51,334	-12,613 Reduced 11.66%	95,577 $293,000
Q3 2024 Nov 14, 2024	BUY	$3.96 - $5.07 $103,613 - $132,656	26,165 Added 31.9%	108,190 $458,000
Q2 2024 Aug 14, 2024	BUY	$3.66 - $5.34 $65,920 - $96,178	18,011 Added 28.14%	82,025 $330,000
Q1 2024 May 14, 2024	BUY	$4.19 - $5.59 $236,755 - $315,862	56,505 Added 752.5%	64,014 $318,000
Q3 2023 Nov 14, 2023	BUY	$2.97 - $3.88 $451 - $589	152 Added 2.07%	7,509 $28,000
Q2 2023 Aug 14, 2023	BUY	$1.69 - $3.24 $12,433 - $23,836	7,357 New	7,357 $23,000
Q2 2021 Aug 12, 2021	SELL	$1.51 - $2.29 $5,420 - $8,221	-3,590 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$1.09 - $2.21 $2,477 - $5,023	-2,273 Reduced 38.77%	3,590 $4,000
Q2 2020 Aug 14, 2020	BUY	$1.8 - $3.05 $108 - $183	60 Added 1.03%	5,863 $15,000
Q4 2019 Feb 13, 2020	BUY	$0.71 - $4.91 $967 - $6,692	1,363 Added 30.7%	5,803 $26,000
Q3 2018 Nov 20, 2018	BUY	$10.49 - $12.87 $7,489 - $9,189	714 Added 19.16%	4,440 $50,000
Q2 2018 Aug 10, 2018	BUY	$8.55 - $13.76 $31,857 - $51,269	3,726 New	3,726 $42,000

Others Institutions Holding SVRA

# of Institutions

133

Shares Held

149M

Call Options Held

67.6K

Put Options Held

29.4K

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $314M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Savara Inc Transaction History